2017年雅思考试阅读模拟题1.doc

2017年雅思考试阅读模拟题10 网络 Changes in Air A A federal ban on ozone-depleting chlorofluorocarbons （CFCs）， to conform with the Clean Air Act, is, ironically, affecting 22.9 million people in the U.S. who suffer from asthma, Genetic inhaled albuterol, which is the most commonly prescribed short-acting asthma medication and requires CFCs to propel it into the lungs, will no longer be legally sold after December 31, 2008. Physicians and patients are questioning the wisdom of the ban, which will have an insignificant effect on ozone but a measurable impact on wallets: the reformulated brand-name alternatives can be three times as expensive, raising the cost to about $40 per inhaler. The issue is even more disconcerting considering that asthma disproportionately affects the poor and that according to recent surveys, an estimated 20 percent of asthma patients are uninsured. B “The decision to make the change was political, not medical or scientific,” says pharmacist Leslie Hendeles of the University of Florida, who co-authored a 2007 paper in the New England Journal of Medicine explaining the withdrawal and transition. In 1987 Congress signed on to the Montreal Protocol on Substances That Deplete the Ozone Layer, an international treaty requiring the phasing out of all nonessential uses of CFCs. At that time, medical inhalers were considered an essential use because no viable alternative propellant existed. In 1989 pharmaceutical companies banded together and eventually, in 1996, reformulated albuterol with hydrofluoroalkane. C The transition began quietly, but as more patients see their prescriptions change and costs go up, many question why this bail must begin before generics become available. At least one member of the FDA advisory committee, Nicholas J. Gross of the Stritch-Loyola School of Medicine, has publicly regretted the decision, recanting his support and requesting that the ban be pushed back until 2010, when the first pat 上一篇英语： 2017年雅思考试阅读模拟题9下一篇英语： 没有了查看更多